Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Rhea-AI Summary
Castle Biosciences (Nasdaq: CSTL) will host a grand opening for its new corporate headquarters in Friendswood, Texas on March 24, 2026 at 3:00 p.m. CT. The purpose-built 23-acre campus features energy-efficient systems, storm-rated design, flexible workspaces and employee amenities.
The facility supports Castle’s clinical testing operations and growth as the company advances its molecular test portfolio; Castle reported $344 million revenue in 2025. The event is by invitation; media may RSVP in advance.
Positive
- None.
Negative
- None.
News Market Reaction – CSTL
In the Mar 4 session, CSTL gained 2.18%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Full-year 2025 results | Positive | -7.3% | Revenue beat guidance and strong core test growth but shares fell afterward. |
| Feb 19 | Clinical validation data | Positive | -6.8% | Prospective JAAD study supported AdvanceAD-Tx performance, yet stock declined. |
| Feb 05 | Earnings date announcement | Neutral | -7.3% | Scheduled Q4 and 2025 earnings release and call details provided. |
| Jan 11 | Preliminary 2025 results | Positive | +0.8% | Preliminary revenue above guidance and strong test volume growth modestly lifted shares. |
| Dec 19 | Inducement equity grants | Neutral | -0.4% | Employee RSU inducement grants under Nasdaq Rule 5635(c)(4) had limited impact. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows multiple instances where positive operational or clinical updates were followed by negative 24-hour price reactions.
Over the last few months, CSTL has reported strong growth, with 2025 revenue of $344.2M exceeding guidance and core test volumes up sharply. It also highlighted positive clinical validation for its AdvanceAD‑Tx test and provided preliminary revenue above prior expectations. Despite this, several of these fundamentally constructive updates saw shares decline in the following session. The new headquarters opening continues a pattern of long-term investment and expansion following the 2025 growth and product launches already disclosed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility.
Local, state and national elected officials are expected to join the event, underscoring the significance of Castle’s investment in the region.
“Opening our new headquarters marks an important milestone for Castle Biosciences,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The facility was built to empower our people, foster collaboration and support the innovations that will drive our future. It reflects our long-term focus on creating an environment where our teams can thrive and continue to make a meaningful difference for patients, as well as our enduring commitment to the Friendswood community that we are proud to call home.”
The new building features modern, flexible workspaces and advanced technology infrastructure designed to meet the Company’s evolving needs. The facility incorporates energy-efficient systems and storm-rated design elements to enhance sustainability and resilience. Employee-focused amenities include a private fitness center, a fourth-floor terrace designed for outdoor collaboration and overflow gatherings adjacent to a 48-seat training center, and a ground-level outdoor patio with a pergola and dedicated food truck pad. The 23-acre wooded campus features two walking trails, providing natural spaces that encourage movement and connection throughout the workday.
Castle, one of the largest publicly traded companies in Galveston County by revenue (
In addition to its Friendswood headquarters, Castle operates clinical laboratories in Phoenix and Pittsburgh. The new headquarters will support Castle’s continued growth as the Company advances its portfolio of innovative molecular tests in areas of high clinical need.
While this event is not open to the public, members of the media are welcome to attend and are encouraged to confirm attendance in advance by contacting Allison Marshall at amarshall@castlebiosciences.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.
We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences, Inc.
